Study of mpox immunity in people who were vaccinated or infected
Part of Infections clinical trials.
This observational study looks at how your body’s defenses work against mpox (monkeypox), based on blood and health information. You may be eligible if you recently got an mpox vaccine or have had mpox infection and are now out of isolation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be able to understand the study information and sign the consent form
- Be 18 years or older, including pregnant or breastfeeding people
- Either (a) plan to get an mpox vaccine within 30 days or already received it, and/or (b) have had mpox infection and are out of isolation at least 30 days after symptoms started
- Be willing and able to complete all study visits and procedures
- Your blood counts should be safe for blood draws (no known significant anemia, and no serious bleeding-related issues)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study in West Africa follows people with confirmed mpox (monkeypox) infection and their close contacts to understand how the virus spreads, clears from the body, and how well the mpox vaccine protects people. You may be eligible if you've recently tested positive for mpox, were exposed to someone with mpox, or live in an area offering mpox vaccination.
This study looks at how well the mpox vaccine works during outbreaks. It tracks people who may have been exposed, those who have been vaccinated or already had mpox, and healthy volunteers.
This study follows people after confirmed mpox, after smallpox vaccination, or in people taking HIV PrEP to learn how the immune system responds over time. It may help scientists better understand protection and immune changes after these exposures.
This is an observational study that follows adults after they get a monkeypox vaccine to learn how their immune system responds. The results may help researchers understand what types of protection the vaccine creates.
This is an observational study that follows people with confirmed monkeypox (mpox) to better understand the illness over time. It may help doctors learn what to expect and improve care, but it does not test a new treatment.
This study tests whether a single dose of the LC16m8 mpox vaccine is safe and works in people living in the Democratic Republic of Congo. It also monitors for side effects and tracks mpox cases to see how well the vaccine protects the community.
Hear when a new Monkeypox trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.